These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 1697693

  • 1. [Hormone therapy in prostate cancer: clinical results].
    Morote-Robles J.
    Rev Esp Fisiol; 1990 Mar; 46(1):59-62. PubMed ID: 1697693
    [Abstract] [Full Text] [Related]

  • 2. Complete androgen blockade for the treatment of prostate cancer.
    Labrie F, Dupont A, Belanger A.
    Important Adv Oncol; 1985 Mar; ():193-217. PubMed ID: 3916740
    [No Abstract] [Full Text] [Related]

  • 3. Endocrine treatment of prostate cancer: standard treatment and new perspectives.
    Boccardo F, Pace M.
    In Vivo; 1993 Mar; 7(5):423-4. PubMed ID: 8110985
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Treatment options in androgen-independent prostate cancer.
    Lara PN, Meyers FJ.
    Cancer Invest; 1999 Mar; 17(2):137-44. PubMed ID: 10071598
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Endocrine treatment of prostate cancer.
    Tammela T.
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Is there a role for pure antiandrogens in the treatment of advanced prostatic cancer?
    Pavone-Macaluso M, Serretta V, Daricello G, Pavone C, Cacciatore M, Romano C, Cavallo N.
    Prog Clin Biol Res; 1990 Nov; 350():149-57. PubMed ID: 2201041
    [Abstract] [Full Text] [Related]

  • 11. Endocrine therapy for prostate cancer.
    Labrie F.
    Endocrinol Metab Clin North Am; 1991 Dec; 20(4):845-72. PubMed ID: 1778180
    [Abstract] [Full Text] [Related]

  • 12. Hormonal management of advanced adenocarcinoma of the prostate.
    Miles BJ.
    Henry Ford Hosp Med J; 1989 Dec; 37(1):16-8. PubMed ID: 2670839
    [No Abstract] [Full Text] [Related]

  • 13. [Hormone therapy for prostate cancer].
    Théodore C.
    Bull Cancer; 2004 Jan; 91(1):69-74. PubMed ID: 14975807
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Endocrine therapy: where do we stand and where are we going?
    Schröder FH.
    Cancer Surv; 1991 Jan; 11():177-94. PubMed ID: 1841751
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Combined radiotherapy and hormone therapy in non-metastatic adenocarcinoma of prostate].
    Lopez S, Simon JM, Mazeron JJ.
    Bull Cancer; 2009 Mar; 96(3):261-70. PubMed ID: 19318304
    [Abstract] [Full Text] [Related]

  • 18. Intermittent androgen deprivation therapy may prolong the duration of androgen dependence of well-differentiated prostate cancer.
    Kaneko Y, Maekawa S, Arakaki R, Okada Y, Terada N, Nishimura K.
    Hinyokika Kiyo; 2006 Apr; 52(4):259-64. PubMed ID: 16686352
    [Abstract] [Full Text] [Related]

  • 19. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.
    Gnanapragasam VJ, Darby S, Khan MM, Lock WG, Robson CN, Leung HY.
    J Pathol; 2005 Jun; 206(2):205-13. PubMed ID: 15818594
    [Abstract] [Full Text] [Related]

  • 20. Hormone therapy in advanced prostate cancer.
    Forster TH, Stoffel F, Gasser TC.
    Front Radiat Ther Oncol; 2002 Jun; 36():49-65. PubMed ID: 11842755
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.